Metabolic mysteries of the inflammatory response: T cell polarization and plasticity

International Reviews of Immunology

Volumn 34, Issue 1, 2015, Pages 3-18

  Fracchia, Kelley M ^a   Walsh, Craig M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aerobic glycolysis; Glucose; Glycolysis; Immunity; Metabolism; Oxidative phosphorylation; T cells

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; INSULIN; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; GLUCOSE; GLUCOSE TRANSPORTER 1; SLC2A1 PROTEIN, HUMAN;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL METABOLISM; CELL POLARITY; CITRIC ACID CYCLE; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HYPOXIA; IMMUNITY; INFLAMMATION; LYMPHOCYTE DIFFERENTIATION; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMORAL IMMUNITY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

CELL DIFFERENTIATION; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; GLYCOLYSIS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INFLAMMATION; LEPTIN; LYMPHOCYTE ACTIVATION; OXIDATIVE PHOSPHORYLATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 84921275837     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2014.974748     Document Type: Review

References (104)

1. Diehn M, Alizadeh AA, Rando OJ, et al. Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc Natl Acad Sci USA. 2002;99:11796-11801.
2. Riley JL, Mao M, Kobayashi S, et al. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc Natl Acad Sci USA 2002;99:11790-11795.
3. Howland KC, Ausubel LJ, London CA, Abbas AK. The roles of CD28 and CD40 ligand in T cell activation and tolerance. J Immunol 2000;164:4465-4470.
4. King CL, Xianli J, June CH, et al. CD28-deficient mice generate an impaired Th2 response to Schistosomamansoni infection. Eur J Immunol 1996;26:2448-2455.
5. Villegas EN, Elloso MM, Reichmann G, et al. Role of CD28 in the generation of effector and memory responses required for resistance to Toxoplasma gondii. J Immunol 1999;163:3344-3353.
6. Rathmell JC, Farkash EA, Gao W, Thompson CB. IL-7 enhances the survival and maintains the size of naive T cells. J Immunol 2001;167:6869-6876.
7. Vander Heiden MG, Plas DR, Rathmell JC, et al. Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol. 2001;21:5899-5912.
8. Rathmell JC, Vander Heiden MG, Harris MH, et al. In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability. Mol Cell. 2000;6:683-692.
9. Jacobs SR, Herman CE, Maciver NJ, et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J Immunol. 2008;180:4476-4486.
10. Pearce EL, Poffenberger MC, Chang CH, Jones RG. Fueling immunity: insights into metabolism and lymphocyte function. Science. 2013;342:1242454.
11. van Stipdonk MJ, Lemmens EE, Schoenberger SP. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol. 2001;2:423-429.
12. Uldry M, Thorens B. The SLC2 family of facilitated hexose and polyol transporters. Pflugers Archiv. Eur J Physiol 2004;447:480-489.
13. Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002;4:648-657.
14. Fujiwara R, Nakai T. Effect of glucose, insulin, and insulin-like growth factor-I on glucose transport activity in cultured rat vascular smooth muscle cells. Atherosclerosis 1996;127:49-57.
15. Inoki K, Ouyang H, Zhu T, et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006;126:955-968.
16. Frauwirth KA, Riley JL, Harris MH, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity 2002;16:769-777.
17. Chakrabarti R, Jung CY, Lee TP, et al. Changes in glucose transport and transporter isoforms during the activation of human peripheral blood lymphocytes by phytohemagglutinin. J Immunol 1994;152:2660-2668.
18. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 2011;27:441-464.
19. Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer 2008;8:51-56.
20. Stentz FB, Kitabchi AE. De novo emergence of growth factor receptors in activated human CD4+ and CD8+ T lymphocytes. Metab Clin Exp 2004;53:117-122.
21. Saucillo DC, Gerriets VA, Sheng J, et al. Leptin metabolically licenses T cells for activation to link nutrition and immunity. J Immunol 2014;192:136-144.
22. Viardot A, Grey ST, Mackay F, Chisholm D. Potential antiinflammatory role of insulin via the preferential polarization of effector T cells toward a T helper 2 phenotype. Endocrinology 2007;148:346-353.
23. Stentz FB, Kitabchi AE. Transcriptome and proteome expression in activated human CD4 and CD8 T-lymphocytes. Biochem Biophys Res Commun 2004;324:692-696.
24. Desbois-Mouthon C, Blivet-Van Eggelpoel MJ, Auclair M, et al. Insulin differentially regulates SAPKs/JNKs and ERKs in CHO cells overexpressing human insulin receptors. Biochem Biophys Res Commun 1998;243:765-770.
25. Singh RA, Zhang JZ. Differential activation of ERK, p38, and JNK required for Th1 and Th2 deviation in myelin-reactive T cells induced by altered peptide ligand. J Immunol 2004;173:7299-7307.
26. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol. 2002;20:55-72.
27. Hansen TK, Thiel S, Wouters PJ, et al. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 2003;88:1082-1088.
28. Takebayashi K, Aso Y, Inukai T. Initiation of insulin therapy reduces serum concentrations of high-sensitivity C-reactive protein in patients with type 2 diabetes. Metab Clin Exp 2004;53:693-699.
29. Jeschke MG, Klein D, Bolder U, Einspanier R. Insulin attenuates the systemic inflammatory response in endotoxemic rats. Endocrinology 2004;145:4084-4093.
30. Frederich RC, Lollmann B, Hamann A, et al. Expression of ob mRNA and its encoded protein in rodents. Impact of nutrition and obesity. J Clin Invest 1995;96:1658-1663.
31. Frederich RC, Hamann A, Anderson S, et al. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1995;1:1311-1314.
32. Procaccini C, Galgani M, De Rosa V, Matarese G. Intracellular metabolic pathways control immune tolerance. Trends Immunol 2012;33:1-7.
33. Procaccini C, Jirillo E, Matarese G. Leptin as an immunomodulator. Mol Aspects Med 2012;33:35-45.
34. Mandel MA, Mahmoud AA. Impairment of cell-mediated immunity in mutation diabetic mice (db/db). J Immunol 1978;120:1375-1377.
35. Chandra RK. Cell-mediated immunity in genetically obese C57BL/6J ob/ob) mice. Am J Clin Nutr 1980;33:13-16.
36. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-1033.
37. Jones RG, Thompson CB. Revving the engine: signal transduction fuels T cell activation. Immunity 2007;27:173-178.
38. Pearce EL. Metabolism in T cell activation and differentiation. Curr Opin Immunol 2010;22:314-320.
39. Warburg O. On the origin of cancer cells. Science 1956;123:309-314.
40. Warburg O. The chemical constitution of respiration ferment. Science 1928;68:437-443.
41. Frauwirth KA, Thompson CB. Regulation of T lymphocyte metabolism. J Immunol 2004;172:4661-4665.
42. Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol 2005;5:844-852.
43. Fracchia KM, Pai CY, Walsh CM. Modulation of T cell metabolism and function through calcium signaling. Front Immunol 2013;4:324.
44. Nathan C, Ding A. Snapshot: Reactive Oxygen Intermediates (ROI). Cell 2010;140:951-951 e952.
45. Gatza E, Wahl DR, Opipari AW, et al. Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease. Sci Transl Med 2011;3:67ra68.
46. Pearce EL, Walsh MC, Cejas PJ, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009;460:103-107.
47. Hamilos DL, Wedner HJ. The role of glutathione in lymphocyte activation. I. Comparison of inhibitory effects of buthionine sulfoximine and 2-cyclohexene-1-one by nuclear size transformation. J Immunol 1985;135:2740-2747.
48. Hampton MB, Orrenius S. Redox regulation of apoptotic cell death in the immune system. Toxicol Lett 1998;102-103:355-358.
49. Haworth RA, Berkoff HA. The control of sugar uptake by metabolic demand in isolated adult rat heart cells. Circ Res 1986;58:157-165.
50. Shetty M, Loeb JN, Vikstrom K, Ismail-Beigi F. Rapid activation of GLUT-1 glucose transporter following inhibition of oxidative phosphorylation in clone 9 cells. J Biol Chem 1993;268:17225-17232.
51. Chang CH, Curtis JD, Maggi LB, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 2013;153:1239-1251.
52. Wang R, Green DR. The immune diet: meeting the metabolic demands of lymphocyte activation. F1000 Biol Rep 2012;4:9.
53. Wang R, Dillon CP, Shi LZ, et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 2011;35:871-882.
54. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 2007;104:19345-19350.
55. Vaughn AE, Deshmukh M. Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nat Cell Biol 2008;10:1477-1483.
56. Wang JB, Erickson JW, Fuji R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010;18:207-219.
57. Tripmacher R, Gaber T, Dziurla R, et al. Human CD4(+) T cells maintain specific functions even under conditions of extremely restricted ATP production. Eur J Immunol 2008;38:1631-1642.
58. Cham CM, Gajewski TF. Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J Immunol 2005;174:4670-4677.
59. Sena LA, Li S, Jairaman A, et al. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity 2013;38:225-236.
60. Devadas S, Zaritskaya L, Rhee SG, et al. Discrete generation of superoxide and hydrogen peroxide by T cell receptor stimulation: selective regulation of mitogen-activated protein kinase activation and fas ligand expression. J Exp Med 2002;195:59-70.
61. Giannoni E, Buricchi F, Raugei G, et al. Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth. Mol Cell Biol 2005;25:6391-6403.
62. Cao J, Schulte J, Knight A, et al. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J 2009;28:1505-1517.
63. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol 2003;552:335-344.
64. Papandreou I, Cairns RA, Fontana L, et al. HIF-1 mediates adaptation to hypoxia by actively down-regulating mitochondrial oxygen consumption. Cell Metab 2006;3:187-197.
65. Berra E, Benizri E, Ginouves A, et al. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 2003;22:4082-4090.
66. Michalek RD, Gerriets VA, Jacobs SR, et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol. 2011;186:3299-3303.
67. Rodriguez-Prados JC, Traves PG, Cuenca J, et al. Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. J Immunol 2010;185:605-614.
68. Michalek RD, Gerriets VA, Nichols AG, et al. Estrogen-related receptor-alpha is a metabolic regulator of effector T-cell activation and differentiation. Proc Natl Acad Sci USA 2011;108:18348-18353.
69. Shi LZ, Wang R, Huang G, et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med 2011;208:1367-1376.
70. Dang EV, Barbi J, Yang HY, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 2011;146:772-784.
71. Huo Y, Iadevaia V, Yao Z, et al. Stable isotope-labelling analysis of the impact of inhibition of the mammalian target of rapamycin on protein synthesis. Biochem J 2012;444:141-151.
72. So L, Fruman DA. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem J 2012;442:465-481.
73. Costello PS, Gallagher M, Cantrell DA. Sustained and dynamic inositol lipid metabolism inside and outside the immunological synapse. Nat Immunol 2002;3:1082-1089.
74. Calleja V, Alcor D, Laguerre M, et al. Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. PLoS Biol 2007;5:e95.
75. Rathmell JC, Fox CJ, Plas DR, et al. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 2003;23:7315-7328.
76. Grumont RJ, Strasser A, Gerondakis S. B cell growth is controlled by phosphatidylinosotol 3-kinase-dependent induction of Rel/NF-kappaB regulated c-myc transcription. Mol Cell 2002;10:1283-1294.
77. Gottlob K, Majewski N, Kennedy S, et al. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 2001;15:1406-1418.
78. Okkenhaug K, Bilancio A, Farjot G, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002;297:1031-1034.
79. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007;408:297-315.
80. Fox CJ, Hammerman PS, Thompson CB. The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med 2005;201:259-266.
81. Turner MS, Kane LP, Morel PA. Dominant role of antigen dose in CD4+ Foxp3 +regulatory T cell induction and expansion. J Immunol 2009;183:4895-4903.
82. Katzman SD, O'Gorman WE, Villarino AV, et al. Duration of antigen receptor signaling determines T-cell tolerance or activation. Proc Natl Acad Sci USA 2010;107:18085-18090.
83. Colombetti S, Basso V, Mueller DL, Mondino A. Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin. J Immunol 2006;176:2730-2738.
84. Zheng Y, Collins SL, Lutz MA, et al. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol 2007;178:2163-2170.
85. Zheng Y, Delgoffe GM, Meyer CF, et al. Anergic T cells are metabolically anergic. J Immunol 2009;183:6095-6101.
86. Nicklin P, Bergman P, Zhang B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009;136:521-534.
87. Maciolek JA, Alex Pasternak J, Wilson HL. Metabolism of activated T lymphocytes. Curr Opin Immunol 2014;27C:60-74.
88. Carbone F, De Rosa V, Carrieri PB, et al. Regulatory T cell proliferative potential is impaired in human autoimmune disease. Nat Med 2014;20:69-74.
89. Nagai S, Kurebayashi Y, Koyasu S. Role of PI3K/Akt and mTOR complexes in Th17 cell differentiation. Ann NY Acad Sci 2013;1280:30-34.
90. Yang K, Chi H. mTOR and metabolic pathways in T cell quiescence and functional activation. Semin Immunol 2012;24:421-428.
91. Duvel K, Yecies JL, Menon S, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 2010;39:171-183.
92. Macintyre AN, Finlay D, Preston G, et al. Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity 2011;34:224-236.
93. Zhou X, Bailey-Bucktrout SL, Jeker LT, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009;10:1000-1007.
94. Freemerman AJ, Johnson AR, Sacks GN, et al. Metabolic Reprogramming of Macrophages: Glucose Transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. J Biol Chem 2014;289:7884-7896.
95. Delgoffe GM, Kole TP, Zheng Y, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009;30:832-844.
96. Peng T, Golub TR, Sabatini DM. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol 2002;22:5575-5584.
97. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int 2001;59:3-16.
98. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+regulatory T cells. Blood 2005;105:4743-4748.
99. Delgoffe GM, Pollizzi KN, Waickman AT, et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol 2011;12:295-303.
100. Sitkovsky MV, Lukashev D, Apasov S, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004;22:657-682.
101. van der Windt GJ, Everts B, Chang CH, et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cellmemory development. Immunity 2012;36:68-78.
102. Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009;460:108-112.
103. Pipkin ME, Sacks JA, Cruz-Guilloty F, et al. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 2010;32:79-90.
104. Finlay DK, Rosenzweig E, Sinclair LV, et al. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J Exp Med 2012;209:2441-2453.